ABA Autism denied as not FDA-approved for this use by Humana?

Humana's specific coverage criteria for aba autism are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied ABA Therapy as "Not FDA-Approved" — and Why You Can Appeal

ABA therapy is a behavioral health service, not a pharmaceutical product, and therefore does not require FDA approval. When Humana issues a "not FDA-approved" denial for ABA, they are applying an investigational or experimental policy standard rather than a meaningful drug-approval standard — and that application is legally and clinically contestable.

ABA is recognized as an evidence-based, standard-of-care treatment for Autism Spectrum Disorder by the American Academy of Pediatrics, the American Psychological Association, the U.S. Surgeon General, and federal Medicaid policy. State autism insurance mandates in the majority of U.S. states independently require coverage of ABA for ASD. The FDA-approval framework simply does not apply to behavioral therapy services.

## Federal Appeal Framework

• ACA §2719 / External Review: You have approximately 180 days from the denial to request independent external review. Expedited review is available when health could be seriously jeopardized. External reviewers routinely reverse experimental/investigational denials of ABA therapy.
• ERISA §503: Humana must provide a written explanation of the specific standard used to classify ABA as unapproved and the evidence basis for that determination.
• MHPAEA: If Humana applies an FDA-approval or evidence standard to ABA that it does not apply to comparable physical rehabilitation services, that disparity is an independent parity violation. Request Humana's written non-quantitative treatment limitation (NQTL) analysis.
• State autism mandate: For fully-insured plans, verify whether your state's autism coverage mandate independently overrides Humana's policy.

## Documentation to Gather

• Professional society endorsements: A letter from the treating physician or BCBA citing the major organizations that recognize ABA as evidence-based and standard-of-care for ASD.
• Diagnosis confirmation: Licensed clinician's written ASD diagnosis.
• Treatment plan and functional assessments: Current severity documentation and individualized clinical goals.
• Humana's coverage policy language: Identify the exact standard being applied to classify ABA as experimental or unapproved, and the plan-document provision invoked.

## Criteria-Mapping Structure

For each element of Humana's investigational/not-approved standard, provide the counter-evidence: professional society recognition, guideline-organization endorsement, and established clinical practice. Explicitly state that the FDA-approval framework does not apply to behavioral therapy and that Humana's policy, as applied, may violate MHPAEA.